ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC), accounting for approximately 15 to 20% of all BCs, represents a heterogeneous group lacking the expression of estrogen and progesterone receptors (ER and PR), as well as human epidermal growth factor receptor 2 (HER2) amplification [2,3].